AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 72 min read$JNJ

Forminard Elizabeth sold $4.1M of JNJ

Forminard Elizabeth (EVP, Chief Legal Officer) sold 15,918 shares of JOHNSON & JOHNSON (JNJ) at an average of $257.00 ($255.93–$257.76, $4.09M total) across 2 trades on 2026-08-06.

Original reporting
SEC EDGAR · Forminard Elizabeth
Published Aug 7, 2026, 9:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$JNJ
Neutral
medium confidence
Mentioned
$JNJ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the company’s EVP and Chief Legal Officer, including trade dates, share count, and total value.

02

Market read

Traders may note insider selling, but the disclosure does not provide new operational or financial guidance for JNJ.

03

What to watch

The filing does not disclose intent, tax context, or whether additional sales occurred around the same period; without that, price reaction should be muted.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-07 after-hours; reflects trades dated 2026-08-06

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralMedium confidence
Context

Johnson & Johnson disclosed via Form 4 that EVP Chief Legal Officer Forminard Elizabeth sold 15,918 shares for about $4.09M on 2026-08-06.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless followed by additional disclosures or company-specific news.

Evidence & confidence

Form 4 provides transaction details but does not indicate new corporate guidance, litigation, or operational changes. The sale size is moderate relative to JNJ and lacks a stated catalyst in the filing.

Market effects

Sector

Insider selling in a mega-cap healthcare name is not a reliable sector signal without broader pattern or sector-specific regulatory/earnings catalysts.

Regional

No clear regional spillover; this is company-specific insider transaction disclosure.

Global

Minimal global relevance; JNJ is widely held, but this filing alone does not change global fundamentals.

Counterpoint

What could challenge this read

The absence of a stated 10b5-1 plan could be misread as bearish; executives may sell for diversification or tax reasons unrelated to outlook.

Key entities

  • issuer
    Johnson & Johnson

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Forminard Elizabeth

    EVP, Chief Legal Officer who sold shares via open-market transactions.

Read at source← All news

Related articles

AUG 4
$JNJMedAI 8/10

Mary Alexander Applauds Historic Johnson & Johnson Talc Settlement, Calling It a Long-Overdue Measure of Justice for Thousands of Women

Attorney Mary Alexander said a proposed minimum $5.5 billion talc settlement involving Johnson & Johnson could compensate tens of thousands of plaintiffs alleging ovarian cancer from J&J talc-based products. Alexander’s firm represents affected women and families, and said J&J denies liability. The settlement follows years of litigation and appeals, with J&J previously seeking bankruptcy resolution.

prnewswire.com2 min
AUG 2
$JNJMedAI 9/10

Johnson & Johnson Secures $2.58 Billion Option To Acquire Sail Biomedicines

Johnson & Johnson agreed with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases and secured an exclusive option to acquire Sail for $2.58 billion. J&J will make $785 million in initial payments, including a $465 million equity investment, plus up to $140 million in milestone payments. J&J expects EPS impact of about -$0.18 in 2026 and -$1.28 in 2027, subject to approvals.

pulse2.com4 min
JUL 31
$JNJMedAI 8/10

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline - Johnson & Johnson

Johnson & Johnson said it will buy Firefly Bio Inc. for $1 billion in cash and partner with Sail Biomedicines, including a $2.58 billion option purchase. The Sail deal includes $785 million upfront and $140 million in development milestones. J&J expects about a $1 billion in-process R&D charge in Q3 2026 and a roughly $0.46 adjusted EPS hit in 2026. JNJ shares were up 0.86% to $258.03.

benzinga.com5 min